|
Mar 12
|
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
|
|
Mar 4
|
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
|
|
Jan 23
|
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
|
|
Jan 2
|
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
|
|
Dec 19
|
Hedge Funds Say These Penny Stocks Are Poised to Explode
|
|
Dec 7
|
Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT)
|
|
Dec 2
|
Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT)
|
|
Sep 6
|
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
|
|
Sep 5
|
MaxCyte to Participate in Baird Global Healthcare Conference
|
|
Apr 28
|
MaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this year
|